Known as mono and the “kissing disease,” infectious mononucleosis is highly contagious and most commonly transmitted through saliva—sharing drinks or kissing someone who is infected. Epstein-Barr virus (EBV) is the most common cause of infectious mononucleosis, yet other viruses can also cause this condition. Symptoms usually appear four to six weeks after infection with EBV, may develop slowly and are known to last for weeks to several months following infection. Mono is most common among teenagers and young adults—at least one out of four will get infected with EBV and develop mono.
“The severe fatigue and malaise associated with mono can last for weeks and can be debilitating for some, leading to hospitalization and prolonged absence from work or school. If left untreated, mono can also lead to complications like liver inflammation and enlarged spleen,” said renowned natural health physician and best-selling author, Dr. Fred Pescatore. “There are no known antibiotics or prescriptions to specifically treat mono. This research on Robuvit provides promising, measurable results for mono patients.”
The new study examined a group of 50 participants who opted into either the test group for Robuvit supplementation or a control group following standard management practices.
Each of these participants tested positive for EBV indicating mono and began their standard management regimen, which included a healthy diet, exercise, and supplementation with small amounts of zinc and copper, and supplementation with Robuvit. Researchers evaluated participant symptoms based on the Karnofsky Performance Scale Index (KPSI), which classifies patients according to their functional impairment and fatigue. Participants in the Robuvit test group supplemented with 300 mg of Robuvit daily for four weeks and reported improvements in most major symptoms of mono, including:
- 87% of participants were free of mono-related fatigue (vs 69% in the control group)
- 92% of participants were free of malaise (vs 73%in the control group)
- 92% of participants were free of long-lasting symptoms (vs 65% in the control group)
- 62% of participants tested negative for swollen nodes in ultrasound exams (vs 38% in the control group)
“This research shows the ability of Robuvit to cut the duration of symptoms and to combat the nagging fatigue that lingers for mono patients. Several studies show Robuvit is a natural energy booster and fatigue-fighter. This study showed that consistent performance even with a condition that is known for its lingering fatigue symptoms,” said Pescatore.
Robuvit French oak wood extract is a powerful natural antioxidant shown to support natural energy and combat the effects of both general fatigue and chronic fatigue syndrome (CFS). This new study builds off of the body of research showing Robuvit’s benefits for natural caffeine-free energy.